美康生物 reported revenue of ¥0.83B for the period ended 2026-06-30, +12.5% year on year. Net income was ¥0.06B, a 7.4% net margin on a 35.5% gross margin. The largest revenue line is 自产产品 at 47% of the total. Free cash flow for the period was ¥0.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.83B | +12.5% |
| Gross profit | ¥0.29B | — |
| Operating income | ¥0.07B | — |
| Net income | ¥0.06B | +10.7% |
| Gross margin | 35.5% | Net margin 7.4% |
| Revenue Q/Q | +20.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 自产产品 | ¥0.39B | 47.5% |
| 代理产品 | ¥0.28B | 33.4% |
| 医学检测服务 | ¥0.14B | 17.0% |
| 其他(补充) | ¥0.02B | 2.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.53B | 64.5% |
| R&D | ¥0.06B | 7.5% |
| SG&A | ¥0.18B | 22.1% |
| Tax & other | ¥0.01B | 0.7% |
| Item | Amount |
|---|---|
| Total assets | ¥3.71B |
| Total liabilities | ¥0.71B |
| Shareholders' equity | ¥3.00B |
| Equity / assets | 80.8% |
| Operating cash flow | ¥0.12B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.11B |
| Cash conversion (OCF / net income) | 102% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
运达科技 ・ 鲍斯股份 ・ 金雷股份 ・ 双杰电气 ・ 康斯特 ・ 航天智造 ・ 全信股份 ・ 浩云科技 ・ 汉邦高科 ・ 创业慧康 ・ 山河药辅 ・ 三鑫医疗
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies